» Articles » PMID: 28507445

Evaluation of Fatigue and Its Correlation with Quality of Life Index, Anxiety Symptoms, Depression and Activity of Disease in Patients with Psoriatic Arthritis

Overview
Publisher Dove Medical Press
Specialty Dermatology
Date 2017 May 17
PMID 28507445
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Psoriatic arthritis is associated with psychosocial morbidity and decrease in quality of life. Psychiatric comorbidity also plays an important role in the impairment of quality of life and onset of fatigue.

Objectives: This study aimed to assess the prevalence of fatigue in psoriatic arthritis patients and to correlate it to quality of life indexes, functional capacity, anxiety, depression and disease activity.

Patients And Methods: This cross-sectional study was performed on outpatients with psoriatic arthritis. Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F; version 4) was used to measure fatigue; 36-Item Short Form Health Survey (SF-36) and Psoriasis Disability Index (PDI) to measure quality of life; Health Assessment Questionnaire (HAQ) to assess functional capacity; Hospital Anxiety and Depression (HAD) scale to measure anxiety and depression symptoms; Psoriasis Area and Severity Index (PASI), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Clinical Disease Activity Index (CDAI) to evaluate clinical activity.

Results: In all, 101 patients with mean age of 50.77 years were included. The mean PDI score was 8.01; PASI score, 9.88; BASDAI score, 3.59; HAQ score, 0.85; HAD - Anxiety (HAD A) score, 7.39; HAD Depression (HAD D) score, 5.93; FACIT-Fatigue Scale (FACIT-FS) score, 38.3 and CDAI score, 2.65. FACIT-FS was statistically associated with PASI ( -0.345, <0.001), PDI ( -0.299, <0.002), HAQ ( -0.460, <0.001), HAD A ( -0.306, =0.002) and HAD D ( -0.339, <0.001). The correlations with CDAI and BASDAI were not confirmed. There was statistically significant correlation with all of the domains of SF-36 and FACIT-F (version 4).

Conclusion: Prevalence of fatigue was moderate to intense in <25% of patients with psoriatic arthritis. Fatigue seems to be more related to the emotional and social aspects of the disease than to joint inflammatory aspects, confirming that the disease's visibility is the most disturbing aspect for the patient and that "skin pain" is more intense than the joint pain.

Citing Articles

The impact of psoriatic arthritis on quality of life: a systematic review.

James L, Hailey L, Suribhatla R, McGagh D, Amarnani R, Bundy C Ther Adv Musculoskelet Dis. 2024; 16:1759720X241295920.

PMID: 39717741 PMC: 11664531. DOI: 10.1177/1759720X241295920.


Potential Mechanism of Fatigue Induction and Its Management by JAK Inhibitors in Inflammatory Rheumatic Diseases.

Felis-Giemza A, Massalska M, Roszkowski L, Romanowska-Prochnicka K, Ciechomska M J Inflamm Res. 2023; 16:3949-3965.

PMID: 37706062 PMC: 10497048. DOI: 10.2147/JIR.S414739.


Burden and Disease Characteristics of Psoriatic Arthritis at a Tertiary Center.

Attar S, Almanmmas A, Alamri S, Sindi A, Jobah M, Bader M Cureus. 2022; 14(7):e27359.

PMID: 36043001 PMC: 9411818. DOI: 10.7759/cureus.27359.


Genetic Variants of the Gene and Risk of Fatigue Among Patients With Primary Sjögren's Syndrome.

Flessa C, Zampeli E, Evangelopoulos M, Natsis V, Bodewes I, Huijser E Front Immunol. 2022; 13:836824.

PMID: 35371038 PMC: 8964489. DOI: 10.3389/fimmu.2022.836824.


Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort study.

Skougaard M, Jorgensen T, Jensen M, Ballegaard C, Guldberg-Moller J, Egeberg A Rheumatol Adv Pract. 2021; 5(3):rkab076.

PMID: 34778701 PMC: 8578691. DOI: 10.1093/rap/rkab076.


References
1.
Calin A, Garrett S, Whitelock H, Kennedy L, OHea J, Mallorie P . A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994; 21(12):2281-5. View

2.
Gladman D, Mease P, Cifaldi M, Perdok R, Sasso E, Medich J . Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis. 2006; 66(2):163-8. PMC: 1798491. DOI: 10.1136/ard.2006.057901. View

3.
Tezel N, Yilmaz Tasdelen O, Bodur H, Gul U, Kulcu Cakmak S, Oguz I . Is the health-related quality of life and functional status of patients with psoriatic arthritis worse than that of patients with psoriasis alone?. Int J Rheum Dis. 2014; 18(1):63-9. DOI: 10.1111/1756-185X.12283. View

4.
Gladman D, Landewe R, McHugh N, FitzGerald O, Thaci D, Coates L . Composite measures in psoriatic arthritis: GRAPPA 2008. J Rheumatol. 2010; 37(2):453-61. DOI: 10.3899/jrheum.090956. View

5.
Wessely S, Lewis G . The classification of psychiatric morbidity in attenders at a dermatology clinic. Br J Psychiatry. 1989; 155:686-91. DOI: 10.1192/s0007125000018201. View